BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit

BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.